A Methodological Approach to Identify Natural Compounds with Antifibrotic Activity and the Potential to Treat Pulmonary Fibrosis Using Single-Cell Sequencing and Primary Human Lung Macrophages
Authors:
- Simon H. ApteSimon H. Apte
- Penny L. GrovesPGPenny L. Groves
- Maxine E. TanMTMaxine E. Tan
- Viviana P. LutzkyVLViviana P. Lutzky
- Tharushi de SilvaTSTharushi de Silva
- Joshua N. MonteithJMJoshua N. Monteith
- Stephanie T. YerkovichStephanie T. Yerkovich
- Brendan J. O’sullivanBOBrendan J. O’sullivan
- Rohan A. DavisRDRohan A. Davis
- Daniel C. ChambersDCDaniel C. Chambers
Open Access
- 12 October 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15104
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of the interstitial pneumonias. The cause of the disease is unknown, and new therapies that stop or reverse disease progression are desperately needed. Recent advances in next-generation sequencing have led to an abundance of freely available, clinically relevant, organ-and-disease-specific, single-cell transcriptomic data, including studies from patients with IPF. We mined data from published IPF data sets and identified gene signatures delineating pro-fibrotic or antifibrotic macrophages and then used the Enrichr platform to identify compounds with the potential to drive the macrophages toward the antifibrotic transcriptotype. We then began testing these compounds in a novel in vitro phenotypic drug screening assay utilising human lung macrophages recovered from whole-lung lavage of patients with silicosis. As predicted by the Enrichr tool, glitazones potently modulated macrophage gene expression towards the antifibrotic phenotype. Next, we assayed a subset of the NatureBank pure compound library and identified the cyclobutane lignan, endiandrin A, which was isolated from the roots of the endemic Australian rainforest plant, Endiandra anthropophagorum, with a similar antifibrotic potential to the glitazones. These methods open new avenues of exploration to find treatments for lung fibrosis.Keywords
Funding Information
- The Common Good, an initiative of The Prince Charles Hospital Foundation (INN2019-41)
This publication has 50 references indexed in Scilit:
- Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary FibrosisCurrent Pathobiology Reports, 2013
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- Pioglitazone Inhibits the Expression of Inflammatory Cytokines From Both Monocytes and Lymphocytes in Patients With Impaired Glucose ToleranceArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Endiandrin A, a Potent Glucocorticoid Receptor Binder Isolated from the Australian Plant Endiandra anthropophagorumJournal of Natural Products, 2007
- PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouseNephrology Dialysis Transplantation, 2006
- The peroxisome proliferator-activated receptor-γ agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined dietHepatology Research, 2005
- Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2on bleomycin-induced lung injuryEuropean Respiratory Journal, 2005
- Peroxisome proliferator–activated receptor γ is expressed in airways and inhibits features of airway remodeling in a mouse asthma modelJournal of Allergy and Clinical Immunology, 2004
- Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined dietBiochemical and Biophysical Research Communications, 2004
- PPARγ Activation Induces the Expression of the Adipocyte Fatty Acid Binding Protein Gene in Human MonocytesBiochemical and Biophysical Research Communications, 1999